BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12880970)

  • 1. Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma.
    Mora J; Gerald WL; Cheung NK
    Cancer Lett; 2003 Jul; 197(1-2):119-24. PubMed ID: 12880970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.
    Mora J; Gerald WL; Qin J; Cheung NK
    Cancer; 2002 May; 94(10):2756-65. PubMed ID: 12173347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
    Mora J; Cheung NK; Chen L; Qin J; Gerald W
    Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma.
    Mora J; Lavarino C; Alaminos M; Cheung NK; Ríos J; de Torres C; Illei P; Juan G; Gerald WL
    Genes Chromosomes Cancer; 2007 Apr; 46(4):385-96. PubMed ID: 17243159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.
    Mora J; Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Fazzari M; Heller G; Chen L; Gerald WL
    J Mol Diagn; 2000 Feb; 2(1):37-46. PubMed ID: 11272900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.
    Yue ZX; Xing TY; Zhao W; Zhao Q; Wang XS; Su Y; Gao C; Liu SG; Ma XL
    Cancer Med; 2022 Apr; 11(8):1837-1849. PubMed ID: 35137546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review.
    Kramer K; Kushner B; Heller G; Cheung NK
    Cancer; 2001 Apr; 91(8):1510-9. PubMed ID: 11301399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
    Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
    Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetics of neuroblastoma and the implications for clinical management: a review of the MSKCC experience.
    Mora J; Gerald WL; Qin J; Cheung NK
    Oncologist; 2001; 6(3):263-8. PubMed ID: 11423673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
    Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
    J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity and clonal evolution in neuroblastoma.
    Mora J; Cheung NK; Gerald WL
    Br J Cancer; 2001 Jul; 85(2):182-9. PubMed ID: 11461074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma.
    Dhooge CR; De Moerloose BM; Benoit YC; Van Roy N; Philippé ; Laureys GG
    Cancer; 1997 Oct; 80(7):1250-7. PubMed ID: 9317175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
    Bowman LC; Castleberry RP; Cantor A; Joshi V; Cohn SL; Smith EI; Yu A; Brodeur GM; Hayes FA; Look AT
    J Natl Cancer Inst; 1997 Mar; 89(5):373-80. PubMed ID: 9060959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
    Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
    Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.
    Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Ambros P; Ambros I; Ladanyi M; Eddy J; Bonilla MA; Gerald W
    Eur J Cancer; 1997 Oct; 33(12):2117-20. PubMed ID: 9516865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.